logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
07/11/2025
Guatemala's economic activity grew by 4.5% year-on-year in September.
Latest
2 m ago
After Reachlife reached an agreement with the White House, including lowering the price of weight loss drugs, its stock price increased further, rising by 2.2% most recently.
3 m ago
American President Trump: Thank you Lilly, Novartis, and Novartis for reaching a drug price agreement with the United States.
4 m ago
Eli Lilly (LLY.N): As part of an agreement with the Trump administration, it will receive a three-year tariff exemption.
4 m ago
According to White House sources, Lilly and Novo Nordisk will repatriate overseas revenue from their existing products and allow Medicaid programs in all states of the United States to benefit from most-favored-nation pricing.
4 m ago
Senior officials in the Trump administration: Eli Lilly and Novo Nordisk will lower the price of GLP-1 medications used to treat diabetes and other indications to $245 per month.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.